 NEW YORK and LONDON, Jan. 04, 2023 GLOBE NEWSWIRE -- Akari Therapeutics, Plc Nasdaq: AKTX, a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari President and CEO Rachelle Jacques will present a company overview at Biotech Showcase 2023 on Monday, January 9, 2023 at 9 am ET. The presentation will include progress highlights from Akaris two priority pipeline programs: a Phase 3 clinical trial of nomacopan, a novel bispecific inhibitor of complement C5 and leukotriene B4 LTB4, for the treatment of severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, and a pre-clinical program investigating long-acting PAS-nomacopan as a potential treatment for geographic atrophy. 